FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2606911774> ?p ?o ?g. }

• W2606911774 endingPage "366" @default.
• W2606911774 startingPage "362" @default.
• W2606911774 abstract "There are no disease-modifying treatments for adult human neurodegenerative diseases. Here we test RNA-targeted therapies in two mouse models of spinocerebellar ataxia type 2 (SCA2), an autosomal dominant polyglutamine disease. Both models recreate the progressive adult-onset dysfunction and degeneration of a neuronal network that are seen in patients, including decreased firing frequency of cerebellar Purkinje cells and a decline in motor function. We developed a potential therapy directed at the ATXN2 gene by screening 152 antisense oligonucleotides (ASOs). The most promising oligonucleotide, ASO7, downregulated ATXN2 mRNA and protein, which resulted in delayed onset of the SCA2 phenotype. After delivery by intracerebroventricular injection to ATXN2-Q127 mice, ASO7 localized to Purkinje cells, reduced cerebellar ATXN2 expression below 75% for more than 10 weeks without microglial activation, and reduced the levels of cerebellar ATXN2. Treatment of symptomatic mice with ASO7 improved motor function compared to saline-treated mice. ASO7 had a similar effect in the BAC-Q72 SCA2 mouse model, and in both mouse models it normalized protein levels of several SCA2-related proteins expressed in Purkinje cells, including Rgs8, Pcp2, Pcp4, Homer3, Cep76 and Fam107b. Notably, the firing frequency of Purkinje cells returned to normal even when treatment was initiated more than 12 weeks after the onset of the motor phenotype in BAC-Q72 mice. These findings support ASOs as a promising approach for treating some human neurodegenerative diseases." @default.
• W2606911774 created "2017-04-28" @default.
• W2606911774 creator A5014464711 @default.
• W2606911774 creator A5015151768 @default.
• W2606911774 creator A5023168018 @default.
• W2606911774 creator A5041249723 @default.
• W2606911774 creator A5041605141 @default.
• W2606911774 creator A5043136568 @default.
• W2606911774 creator A5049001893 @default.
• W2606911774 creator A5056686380 @default.
• W2606911774 creator A5073764338 @default.
• W2606911774 creator A5079071423 @default.
• W2606911774 creator A5083296071 @default.
• W2606911774 date "2017-04-12" @default.
• W2606911774 modified "2023-10-17" @default.
• W2606911774 title "Antisense oligonucleotide therapy for spinocerebellar ataxia type 2" @default.
• W2606911774 cites W1569018103 @default.
• W2606911774 cites W1601653849 @default.
• W2606911774 cites W169228635 @default.
• W2606911774 cites W1893569554 @default.
• W2606911774 cites W1895913202 @default.
• W2606911774 cites W1970986383 @default.
• W2606911774 cites W1993513971 @default.
• W2606911774 cites W1998880168 @default.
• W2606911774 cites W2008512986 @default.
• W2606911774 cites W2024349542 @default.
• W2606911774 cites W2025887362 @default.
• W2606911774 cites W2026155080 @default.
• W2606911774 cites W2059474870 @default.
• W2606911774 cites W2061108287 @default.
• W2606911774 cites W2067730935 @default.
• W2606911774 cites W2081245925 @default.
• W2606911774 cites W2088707712 @default.
• W2606911774 cites W2104979554 @default.
• W2606911774 cites W2115643028 @default.
• W2606911774 cites W2115807468 @default.
• W2606911774 cites W2124985265 @default.
• W2606911774 cites W2126680318 @default.
• W2606911774 cites W2128768698 @default.
• W2606911774 cites W2132758779 @default.
• W2606911774 cites W2154490775 @default.
• W2606911774 cites W2158305904 @default.
• W2606911774 cites W2290803129 @default.
• W2606911774 cites W2401171931 @default.
• W2606911774 cites W2408064656 @default.
• W2606911774 cites W2431977441 @default.
• W2606911774 cites W2606848380 @default.
• W2606911774 doi "https://doi.org/10.1038/nature22044" @default.
• W2606911774 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6625650" @default.
• W2606911774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28405024" @default.
• W2606911774 hasPublicationYear "2017" @default.
• W2606911774 type Work @default.
• W2606911774 sameAs 2606911774 @default.
• W2606911774 citedByCount "252" @default.
• W2606911774 countsByYear W26069117742017 @default.
• W2606911774 countsByYear W26069117742018 @default.
• W2606911774 countsByYear W26069117742019 @default.
• W2606911774 countsByYear W26069117742020 @default.
• W2606911774 countsByYear W26069117742021 @default.
• W2606911774 countsByYear W26069117742022 @default.
• W2606911774 countsByYear W26069117742023 @default.
• W2606911774 crossrefType "journal-article" @default.
• W2606911774 hasAuthorship W2606911774A5014464711 @default.
• W2606911774 hasAuthorship W2606911774A5015151768 @default.
• W2606911774 hasAuthorship W2606911774A5023168018 @default.
• W2606911774 hasAuthorship W2606911774A5041249723 @default.
• W2606911774 hasAuthorship W2606911774A5041605141 @default.
• W2606911774 hasAuthorship W2606911774A5043136568 @default.
• W2606911774 hasAuthorship W2606911774A5049001893 @default.
• W2606911774 hasAuthorship W2606911774A5056686380 @default.
• W2606911774 hasAuthorship W2606911774A5073764338 @default.
• W2606911774 hasAuthorship W2606911774A5079071423 @default.
• W2606911774 hasAuthorship W2606911774A5083296071 @default.
• W2606911774 hasBestOaLocation W26069117742 @default.
• W2606911774 hasConcept C104317684 @default.
• W2606911774 hasConcept C111599444 @default.
• W2606911774 hasConcept C129312508 @default.
• W2606911774 hasConcept C14363569 @default.
• W2606911774 hasConcept C169760540 @default.
• W2606911774 hasConcept C185592680 @default.
• W2606911774 hasConcept C2779500118 @default.
• W2606911774 hasConcept C2780906641 @default.
• W2606911774 hasConcept C2908938912 @default.
• W2606911774 hasConcept C54355233 @default.
• W2606911774 hasConcept C552990157 @default.
• W2606911774 hasConcept C70721500 @default.
• W2606911774 hasConcept C86803240 @default.
• W2606911774 hasConceptScore W2606911774C104317684 @default.
• W2606911774 hasConceptScore W2606911774C111599444 @default.
• W2606911774 hasConceptScore W2606911774C129312508 @default.
• W2606911774 hasConceptScore W2606911774C14363569 @default.
• W2606911774 hasConceptScore W2606911774C169760540 @default.
• W2606911774 hasConceptScore W2606911774C185592680 @default.
• W2606911774 hasConceptScore W2606911774C2779500118 @default.
• W2606911774 hasConceptScore W2606911774C2780906641 @default.
• W2606911774 hasConceptScore W2606911774C2908938912 @default.
• W2606911774 hasConceptScore W2606911774C54355233 @default.
• W2606911774 hasConceptScore W2606911774C552990157 @default.

• next